Kathleen N. Moore, MD, MS / Kristi Jhangiani, PharmD, BCPS - Managed Care Implications of the Expanding Role of PARP Inhibitors in Oncology: Evolving Evidence Base, Current Value Assessment Frameworks
Go online to PeerView.com/QQX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PARP inhibitors have transformed the treatment of multiple cancers in recent years. Indeed, many agents have yielded promising clinical data and received regulatory approval for a number of solid tumors, providing newer alternatives for cancer patients, especially those with limited therapeutic options. Key clinical aspects associated with maximizing the potential of PARP inhibitors in cancer care include application of recommended testing strategies to guide patient selection, individualized treatment planning, and management of treatment-related toxicities. In this web broadcast, oncology and pharmacy experts review the latest evidence on the use of PARP inhibitors in the treatment of different tumors, including breast, ovarian, pancreatic, and prostate cancers, as well as oncology value assessment frameworks and strategies for assessing the benefits, risks, and costs to guide decisions regarding the use of this class of agents. Additionally, practical guidance is provided for optimizing outcomes for cancer patients who may benefit from PARP inhibitor therapy in managed care settings. Upon completion of this activity, participants should be better able to: Discuss the rationale for use and the expanding role of PARP inhibitors in the treatment of different cancers, including ovarian, breast, pancreatic, prostate, and other malignancies, Assess the PARP inhibitors in terms of their mechanisms of action, efficacy and safety profiles, requirements for predictive testing to guide patient selection, nuances of administration and use, and other factors relevant to their value assessment in managed care settings, Implement appropriate decisions regarding the integration and use of PARP inhibitors in cancer care in managed care settings based on balanced assessments of all the evidence and unique characteristics of this class of agents.